Hollow cheeks and sagging skin are driving more weight-loss patients to the plastic surgeon; a new survey finds.
A new study finds calorie labels make a small but potentially significant impact on food selection and calorie intake.
U.S. News & World Report, working with leading medical and nutrition experts, reveals a list of the best diets for overall health and specific conditions.
New study examines U.S. trends in body mass index and obesity and finds improving numbers, driven in part by GLP-1 weight-loss drugs.
New research shows GLP-1 agonists, like Ozempic, and SGLT2 inhibitors, like Farxiga, help lower the risk of secondary stroke, heart attack and death in stroke survivors.
Researchers find no link between semaglutide, the main ingredient in Ozempic and Wegovy, and depression, suicidal thoughts or behaviors in patients with no prior history of the conditions.
Juice cleanses are a popular way to kickstart a health journey, but these diets may do more harm than good in as little as three days.
A study published recently in the journal Nutrients found that consuming ...
Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their intake.
The research found that, compared to placebo, weekly injections of semaglutide (also marketed for weight loss as
“Yo-yo” dieting -- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people with type 1 diabetes, a new study warns.
Diabe...
Weight-loss surgery can protect the liver health of patients with obesity and fatty liver disease, a new study reports.
Patients had a 72% lower risk of developing serious complications of liver disease after undergoing weight-loss surgery, researchers reported in Jan. 2...
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even
Black people with obesity are less likely to get weight-loss surgery than others.
Black people are just as likely to discuss the procedure with their doctor -- nearly 10%, compared with 9% of patients of other races, researchers said.
But only about 8% of those Bla...
The way obesity is diagnosed needs to become more sophisticated, an international commission has concluded.
Using body-mass index (BMI) to tell who is overweight or obese is not reliable, and can result in misdiagnosis, the Commission on Clinical Obesity says in a new pa...
When it comes to living a longer life, staying active may matter far more than what the scale says.
Per the largest study yet on fitness, body weight, and longevity published recently in the
A new diet is on the New Year’s resolution list for nearly half of U.S. adults, according to a new survey from the Physicians Committee for Responsible Medicine.
However, many plan to pick up diets with dicey track records, survey results show.
About 46% of a...
Wondering which popular diet will help you shed extra weight in a healthy way this year?
The Mediterranean diet tops the best diet categories in the U.S. News & World Report 2025 edition.
According to the report, the eating style that refers to the traditional ...
THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes.
The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss meds, a new study finds.
Data on almost 17 million adults natio...
People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their odds for a dangerous blood clot, new research finds....
The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs' cost should be covered by Medicare, Medicaid and private insure...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
"Given the increased interest around obesity medications, we conducted this study to help health care providers and patie...
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.<...
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm.
In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the org...
So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where decadent food will be served in abundance.
Luckily, one expert from Baylor College of Medicine has tips...
America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows.
The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart attack or death, a new study says.
GLP-1 weight-loss...
It may seem counter-intuitive, but losing weight without even trying may not be a good thing.
"It's not typical to have a noticeable drop in weight without changing how much you're eating, being more physically active or trying to lose weight," said dietitian
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths.
“Honestly, I’m quite al...
Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discov...
The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found.
People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy -- had a nearly 14% dec...
The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows.
Patients taking semaglutide -- the active agent in Ozempic and Wegovy -- had as ...
As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.
Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and...
Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says.
People with type 2 diabetes taking semaglutide appeared to have a significantly...
Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 deaths a year...
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list.
As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts.
But a new study involving more than 54,000 U.S. adolescents found no such...
Results from a very small study suggest that a combination of the diabetes drug Ozempic and an innovative new intestinal procedure could help erase the need for insulin in folks with type 2 diabetes.
The new trial hasn't yet been published in a peer-reviewed journal and...
The key to weight loss could come down to a combination of 14 “skinny genes,” a recent study says.
People with these genes dropped twice as much weight through regular exercise compared to those without the genes, researchers found.
Those with the most ...
When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the medications in their health insurance plans, a new survey shows.
Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy.
Now, research finds this scenario is more lik...
In a finding that suggests Ozempic and Wegovy have powers that extend beyond weight loss, a new study finds the medications might also lower people’s risk of opioid overdose.
...
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its block...
Heavy-duty endurance exercise can cause body fat levels to drop without any accompanying weight loss, a new small-scale study indicates.
A group of eleven middle-aged men who cycled 710 miles in seven days lost only about 1% of their total weight, because they ate and dr...
Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days.
They’re in short supply, and often too expensive to afford without insurance cover...
Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that.
In a new decades-long study, veterans with diabetes...
Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same hormone associated with blood sugar and appetite, a new study finds.<...
Initially approved to treat type 2 diabetes, Ozempic and Mounjaro also can help people with type 1 diabetes lose weight and control their blood sugar levels, a n...
Statistics from 2023 on U.S. obesity rates bring no good news: In every state in the nation, 1 in every 5 people is now obese, the new tally shows.
In 2013, not one state had an adult obesity rate topping 35%, but 10 years later 23 states had achieved that dubious distin...
The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval.
All doses of tirzepatide consistently reduced weight in...
Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new clinical trial shows.
The drugs’ a...
The weight-loss drug liraglutide helped obese children lower their BMI and reach a healthier weight, researchers report.
The findings, published Tuesday in the New England Journal of Medicine and...
An experimental weight-loss pill appears to help people quickly shed pounds, a new study says.
People who took the drug amycretin lost up to 13% of their body weight over three months, according to early clinical trial results presented at the European Association for th...
Losing weight can help a person with obesity -- especially those with diabetes -- fend off serious infections, new data shows.
It's an important finding, since "up to one in three hospitalizations in people with diabetes are for infections and people with diabetes are tw...
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the weekly injections they now take, a new study demonstrates.
...
The booming popularity of the weight-loss drug semaglutide has prompted increasing concerns about potential side effects from taking Ozempic or
Folks taking weight-loss drugs like Wegovy or Zepbound might think they’ve found a shortcut to better health.
But they sti...